Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

BI-2536

Inh 755038-02-9 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
Catalog No. ABIN7233234
  • Application
    Inhibition (Inh)
    Purpose
    Dual Plk/BRD4 inhibitor, Destabilizes Myc
    Characteristics
    BI 2536 was originally reported as a potent (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) and selective2 Polo-like kinase inhibitor (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) that caused mitotic arrest and apoptosis induction in various human cancer cell lines. It was later found to be a potent inhibitor (IC50 = 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells. BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.
    Purity
    >97 %
    Chemical Name
    4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
    Formula
    C28H39N7O3
    Solubility
    Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)
  • Restrictions
    For Research Use only
  • Format
    Powder
    Storage
    -20 °C
  • Background
    Apoptosis inducer,Epigenetics,Cell cycle,Myc,Bromodomain,Ubiquitin/Proteasome,Cell death,Cancer,Posttranslational modification,Chromatin
    Molecular Weight
    521.67
    CAS-No
    755038-02-9
You are here:
Support